Successful treatment with nilotinib after bosutinib-induced pulmonary arterial hypertension recurrence following dasatinib in chronic myeloid leukemia in chronic phase

A 52-year-old man was diagnosed with chronic myeloid leukemia in the chronic phase (CML-CP). He experienced bosutinib-induced pulmonary arterial hypertension (PAH) recurrence following dasatinib use. Symptoms and examination findings associated with PAH improved after bosutinib cessation. Although n...

Descripción completa

Detalles Bibliográficos
Autores principales: Takatsuka, Ibuki, Hirata, Hiroya, Takahashi, Takumi, Dohtan, Satoshi, Oka, Shinichiro, Sakamoto, Nami, Takaba, Masamitsu, Adachi, Miwa, Takemura, Tomonari, Nagata, Yasuyuki, Ono, Takaaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9059076/
https://www.ncbi.nlm.nih.gov/pubmed/35509967
http://dx.doi.org/10.1016/j.lrr.2022.100312
Descripción
Sumario:A 52-year-old man was diagnosed with chronic myeloid leukemia in the chronic phase (CML-CP). He experienced bosutinib-induced pulmonary arterial hypertension (PAH) recurrence following dasatinib use. Symptoms and examination findings associated with PAH improved after bosutinib cessation. Although nilotinib was started because of the loss of response after bosutinib cessation, a deep molecular response without PAH recurrence was achieved 3 months after the initiation of nilotinib therapy. PAH recurrence after switching to bosutinib due to dasatinib-induced PAH should be closely monitored. In addition, nilotinib therapy might be an effective approach in PAH cases related to dasatinib and/or bosutinib in patients with CML-CP.

Ejemplares similares